Clinical trial
An Open-label, Single-center, 6-month Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04499963 is registered in ClinicalTrials.gov with Richard Bedlack, M.D., Ph.D. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-center, 6-month Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Richard Bedlack, M.D., Ph.D.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 28, 2020
- Completion date
- August 30, 2022
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.